INCHEON, Korea – August 17 2023 – Samsung Bioepis Co., Ltd. today announced that it has received two ISO certifications: ISO 27001 (Information Security Management System) and ISO 45001 (Occupational Safety & Health Management System) and from the British Standards Institution (BSI) and Lloyd’s Register Quality Assurance, respectively, underscoring the company’s commitment to providing healthy and safe workplace environment and ensuring information security. 

“We are proud that we have obtained ISO 27001 and ISO 45001 certifications. This is a testament that we uphold high standards for occupational health and safety, and information security,” said Christopher Hansung Ko, President and Chief Executive Officer at Samsung Bioepis. “We will keep implementing rigorous standards and practices to ensure the safety of our employees and reduce safety and security risks.”

ISO 27001 is a standard that sets out the requirements for establishing and implementing information security management system and managing risks related to the security of data owned or handled by the company, while ISO 45001 provides a framework for identifying and managing risks related to the health and safety of employees and stakeholders. 

The latest two ISO certifications follow the company’s ISO 14001 (Environmental Management System) and ISO 50001 (Energy Management System).

In June, Samsung Bioepis released its 2023 sustainability report, highlighting its progress towards building more sustainable and socially responsible practices in research and development (R&D), clinical trials, manufacturing, and supply chain management. The report provides a comprehensive overview of the company’s performance and management of its commitment to sustainability, and initiatives on sustainability can be found in the full report: https://bit.ly/3NR2obo  

# # #

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology and gastroenterology. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.